Mesoporous Silica Nanoparticles for Quercetin-Controlled Delivery to Protect Cisplatin-Induced Ototoxicity
Authors:
Open Access
- 3 November 2025
- journal article
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 8 (11) , 10419-10435
Abstract
Cisplatin (CDDP), a widely used chemotherapeutic agent, is limited by severe ototoxicity side effects. Local drug delivery via the middle ear represents the most effective approach for treating inner ear disease. However, therapeutic efficacy is constrained by poor middle ear retention and limited permeability across the round window membrane (RWM). Quercetin (QU) exhibits potent activity against CDDP-induced cytotoxicity but suffers from delivery challenges. To address this, we developed amino-functionalized mesoporous silica nanoparticles (NH2-MSNs) loaded with QU (QU-N-MSNs), leveraging the permselective properties of the RWM. This system was noninvasively administered to the cochlea via trans-tympanic delivery. The synthesized QU-N-MSNs demonstrated a uniform particle size of approximately 116-124 nm, positive charge, and sustained drug release properties. Compared to free QU, QU-N-MSNs demonstrated significantly enhanced antiapoptotic and cytoprotective activities in vitro. In vivo studies confirmed nanoparticle retention within the inner ear for ≥14 days post administration and efficient RWM penetration. Pretreatment with QU-N-MSNs prior to CDDP exposure in murine models substantially mitigated ototoxicity, as evidenced by reduced hearing threshold shifts across multiple frequencies, preservation of hair cells (HCs) and spiral ganglion neurons (SGNs), and attenuation of mitochondrial-mediated SGN apoptosis. These findings establish QU-N-MSNs as an effective RWM-penetrating delivery platform, offering a promising strategy to enhance hydrophobic drug bioavailability in the inner ear and prevent CDDP-induced ototoxicity.Keywords
Funding Information
- Jiangsu Provincial Key Research and Development Program (BE2023653)
- Nanjing Drum Tower Hospital
- Nanjing University (2025-LCYT-ZD-01)
- National Natural Science Foundation of China (82192862, 82201286, 82571318)
- Jiangsu Provincial Medical Key Discipline (Laboratory) (ZDXK202243)
This publication has 80 references indexed in Scilit:
- The caspase-inhibitor Emricasan efficiently counteracts cisplatin- and neomycin-induced cytotoxicity in cochlear cellsJournal of Molecular Medicine, 2024
- Silica nanoparticles: A review of their safety and current strategies to overcome biological barriersAdvanced Drug Delivery Reviews, 2023
- Biosafety of mesoporous silica nanoparticles; towards clinical translationAdvanced Drug Delivery Reviews, 2023
- Advance in the pharmacological effects of quercetin in modulating oxidative stress and inflammation related disordersPhytotherapy Research, 2023
- Development of peptide-based biosensors for detecting cross-linking and deamidation activities of transglutaminasesAmino Acids, 2023
- Adhesive and Injectable Hydrogel Microspheres for Inner Ear TreatmentSmall, 2022
- Direct nose to the brain nanomedicine delivery presents a formidable challengeWIREs Nanomedicine and Nanobiotechnology, 2021
- Analysis of single, cisplatin‐induced DNA bends by atomic force microscopy and simulationsJournal of Molecular Recognition, 2018
- Advances in nano-based inner ear delivery systems for the treatment of sensorineural hearing lossAdvanced Drug Delivery Reviews, 2017
- Mesoporous Silica Supraparticles for Sustained Inner‐Ear Drug DeliverySmall, 2014